Stock Ratings / Health Care / APRE / options

FBLG (36) XCUR (32) ACXP (33) ENVB (34) ⌘ Pro Terminal →

Aprea Therapeutics Inc. (APRE) Options Positioning, Max Pain & Unusual Sweeps

$0.48 -1.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.48

Aprea Therapeutics Inc. (APRE) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $6.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APRE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Aprea Therapeutics Inc. (NASDAQ: APRE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.48 (-1.82% 1D, market cap $6.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APRE ranks #541 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APRE compare to FBLG and XCUR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APRE carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, APRE leads on earnings multiple (N/A) while APRE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APRE?

▼

Per APRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001781983), Aprea Therapeutics Inc. generated $0 in revenue, -$12.6M in net income, and -$12.9M in free cash flow against $15.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.48 (-0.52%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APRE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY APRE SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.59-10.2% Next Q

Q2 (-2Q)

Grade D$0.53-15.1% Next Q

Q3 (-1Q)

Grade D$0.45+6.7% Next Q

Current

Grade D-$0.48-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APRE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APRE currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.69) and Max Pain ($0.50) forces dealer call-delta covering toward $1.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (APRE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for APRE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APRE)

✓Walkthrough of APRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.86%📐 HORIZONTAL RANGE

2026-11-02O $0.53H $0.53L $0.48C $0.48VOL 171.1K

RES: $1.22SUP: $0.40SMA50: $0.69SMA200: $0.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APRE Butterfly Map → + Track APRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APRE)

Health Care Rank #541 of 1016 ⚔️ FBLG vs APRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APRE vs. FBLG, XCUR, ACXP, ENVB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aprea Therapeutics Inc. (APRE) ranks #541 by composite RQD confidence (40/100, grade D-) and #925 by equity capitalization ($6.2M). Within this direct 5-issuer industry benchmark cohort, APRE leads on earnings valuation at N/A trailing P/E, while APRE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APRE ACTIVE Aprea Therapeutics Inc.	D-	40/100	—	—	-35.0%	-1.82%	$6.2M	Benchmark Subject
FBLG FibroBiologics Inc.	D-	36/100	—	—	-35.0%	+0.21%	$6.3M	/fblg-vs-apre →
XCUR Exicure Inc.	E	32/100	—	—	-35.0%	+8.05%	$6.1M	/xcur-vs-apre →
ACXP Acurx Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-2.80%	$5.9M	/acxp-vs-apre →
ENVB Enveric Biosciences Inc.	E	34/100	—	—	-35.0%	-2.06%	$6.5M	/envb-vs-apre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001781983

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aprea Therapeutics Inc. (APRE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.6M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (+5.0% YoY). On the balance sheet, APRE closed FY2025 with $15.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.6M	-$12.9M	-$12.9M	$15.9M	—
FY2024 (FY)	2024-12-31	$0	-$13.0M	-$13.6M	-$13.6M	$24.0M	—
FY2023 (FY)	2023-12-31	$0	-$14.3M	-$12.2M	-$12.2M	—	—

3. APRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does APRE compare to FBLG and XCUR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for APRE?

Where is APRE trading relative to its 50-day, 200-day, and 52-week technical levels?

APRE last traded at $0.48 (-1.82% on volume of 167,611 shares), positioning the stock -30.43% below its 50-day simple moving average ($0.69) and -36.00% below its 200-day simple moving average ($0.75). Across its 52-week range of $0.41 to $1.49, APRE sits at the 6.5% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.54).

APRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is APRE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for APRE.

Direct Sub-Reports: APRE RQD Cockpit APRE 12M Forecast APRE Earnings & Move APRE Dividends & DRIP APRE Insiders & 13F APRE Whale Options APRE Profit Sankey APRE News & Why

Sector Peer Dials

Acurx Pharmaceuticals Inc.

33 /100

ENVB E

Enveric Biosciences Inc.

APRE Core Snapshot

Market Cap $6.2M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $0.44

FREE TRADER TOOLS

Own APRE Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With APRE → 🏆 Trade APRE in $100K Prop Arena →

APRE Wire

Why It Moved →

Direct Company Event TradingView • 14h ago

Aprea Therapeutics, Inc. Estimates – NASDAQ:APRE

Direct Company Event Yahoo Finance UK • 17h ago

Aprea Therapeutics, Inc. (APRE) Seasonal returns chart

Direct Company Event GlobeNewswire • 20h ago

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Direct Company Event The Manila Times • 23h ago

Aprea Therapeutics to Present at October Conferences

Direct Company Event MarketBeat • 1d ago

Aprea Therapeutics Q3 2026 Earnings Date and Estimates

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

APRE — Aprea Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, APRE scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is the cash engine: the source data reports no revenue in each listed fiscal year and an FCF yield of 0%, so the rating reflects an operating business that is consuming cash rather than generating it. The forensic pillar is middling rather than distressed, with an Altman Z of 2.5 and a Piotroski F of 2/9, which signals weak financial strength on the scoring framework provided. Institutional and insider flow pillars are also below midpoint. Upside drivers implied by the data are limited to the trading-level observations (a 52-week range of $0.41 to $1.49 and a current price of $0.49 that sits near the low end of that range); any valuation tradeoff rests on whether the company can fund operations, which the source data does not resolve. Investors should weigh the rating as a risk-screening output, not a forecast.

Business

Aprea Therapeutics Inc. (APRE) is a NASDAQ-listed issuer in the Health Care sector, industry classified as Biotechnology: Pharmaceutical Preparations. Per the profile, the company's market capitalization is $0.0B in that section, while the market data section reports $6.2M. The source data does not describe the company's products, customers, or revenue model. Revenue is reported as $0.0M in each listed fiscal year, so the source data does not show how the company monetizes its activities.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-13.2M	$-12.6M	N/A	$-12.9M	$14.6M	N/A
FY 2024	$0.0M	$-14.3M	$-13.0M	N/A	$-13.6M	$22.8M	N/A
FY 2023	$0.0M	$-15.5M	$-14.3M	N/A	$-12.2M	N/A	N/A

Per the SEC financials, the company reported operating losses across all three listed periods, with gross, operating, and net margins each recorded at 0%. ROIC is -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash declined from $22.8M at FY 2024 to $14.6M at FY 2025, consistent with the negative free cash flow in those periods.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six wire items reference APRE: a TradingView estimates report; a Yahoo Finance UK seasonal returns chart; a GlobeNewswire item announcing a Pre-ESMO Virtual Panel on the state of WEE1 inhibition in precision oncology; a Manila Times item referencing October conferences; a MarketBeat item on the Q3 2026 earnings date and estimates; and a Benzinga after-market mover roundup. All items carry a YELLOW light and MARKET WIRE impact label. The clearest company-specific catalysts in the source data are the conference presentations and the upcoming Q3 2026 earnings. The source data does not provide the content of the conference panel or presentations beyond their titles. Risk watch items include the continued operating losses and cash decline reflected in the financials. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for APRE. A prospective investor should note that the absence of mapped links is a gap in the data rather than evidence of independence. The 2nd-order exposures that would normally matter for a clinical-stage pharmaceutical issuer, such as partner or licensing dependencies, are not resolved by the source data.

Open Questions

What is the company's pipeline and the status of its WEE1 inhibition programs, and does the source data support any revenue-generating arrangement?
How long can current cash of $14.6M (FY 2025) fund operating losses of $-13.2M at the reported run-rate, and what financing options exist?
Why are EPS, debt, and P/E values absent from the source data, and would reported share count explain the $0.49 price against a $6.2M market capitalization?
What is the source of the discrepancy between the $0.0B market capitalization in the profile and the $6.2M in the market data?
What institutional or insider ownership exists, given that the holders section is empty?

APRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aprea Therapeutics Inc. (APRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APRE Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 14h ago

Aprea Therapeutics, Inc. Estimates – NASDAQ:APRE

TradingView report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

Aprea Therapeutics, Inc. (APRE) Seasonal returns chart

Yahoo Finance UK report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 20h ago

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

GlobeNewswire report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 23h ago

Aprea Therapeutics to Present at October Conferences

The Manila Times report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Aprea Therapeutics Q3 2026 Earnings Date and Estimates

MarketBeat report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's After-Market Session - SCWorx (NASDAQ:WORX), XORTX Therapeutic

Benzinga report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

APRE: WEE1’s promise hinges on matching biomarker-defined patients with durable activity and safer dosing

TradingView report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Protalix BioTherapeutics, Inc. (PLX) Seasonal Returns Chart

Yahoo! Finance Canada report covering Aprea Therapeutics Inc. (APRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APRE Bull vs. Bear Conversation Board — What's Your Call at $0.48?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APRE 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.43 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is APRE (D- • RQD 40/100) a Buy at $0.49?

Welcome to the APRE (Aprea Therapeutics Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.39 (-20.4%)

Spot @ $0.49

Pump the brakes on APRE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on APRE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aprea Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.58 (+18.4%)

Spot @ $0.49

APRE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on APRE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.49 (52-wk range $0.41 - $1.49), any beat on forward guidance forces shorts and underweight funds to chase.